## Abstract ## Objective To develop a clinical pharmacogenetic model to predict the efficacy of methotrexate (MTX) in rheumatoid arthritis (RA). ## Methods Two hundred five patients with newly diagnosed RA and active disease were treated with MTX (initiated at a dosage of 7.5 mg/week and increas
How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis
β Scribed by Henk Visser; Saskia le Cessie; Koen Vos; Ferdinand C. Breedveld; Johanna M. W. Hazes
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 106 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Susceptibility to rheumatoid arthritis (RA) maps to residues QKRAA/QRRAA in the third hypervariable region of the HLA DRI31 chain. Peptides from the same area of MHC class II molecules are able to modulate the T-cell repertoire by deleting self-reactive T-cells. The Epstein Barr virus glycoprotein g
## Abstract ## Objective To identify, in conservatively treated, very early arthritis patients, predictors of β₯1 erosion(s) at 2 years, and to construct a prediction model. ## Methods Communityβbased adults (n = 310) who had never taken diseaseβmodifying antirheumatic drugs (DMARDs) or steroids
## Abstract ## Objective In patients with undifferentiated arthritis (UA), methotrexate is effective for inhibiting symptoms, structural damage, and progression to rheumatoid arthritis (RA). However, 40β50% of patients with UA experience spontaneous remission. Thus, adequate decisionβmaking regard